DANBIO: a nationwide registry of biological therapies in Denmark

Clin Exp Rheumatol. Sep-Oct 2005;23(5 Suppl 39):S205-7.

Abstract

Since the year 2000, Danish rheumatologists have been collecting data on a routine basis in the nationwide DANBIO registry, which includes all rheumatologic patients receiving biological drugs. Demographic data, markers of disease activity, current treatment, serious and non-serious adverse events and reasons for discontinuation are registered at each visit either on paper forms or on-line. By June 2005, approximately 3000 treatment courses (18,000 visits) were in the registry, corresponding to close to 90% of eligible patients. Rheumatoid arthritis was the most prevalent diagnosis (75%) followed by ankylosing spondylitis (11%) and psoriatic arthritis (7%). Infections occurred in 43% of the treatment series.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antirheumatic Agents / therapeutic use*
  • Biological Products / therapeutic use*
  • Databases, Factual
  • Denmark
  • Female
  • Humans
  • Longitudinal Studies
  • Male
  • Prognosis
  • Registries*
  • Rheumatic Diseases / diagnosis
  • Rheumatic Diseases / physiopathology
  • Rheumatic Diseases / therapy*
  • Rheumatology / methods*
  • Severity of Illness Index

Substances

  • Antirheumatic Agents
  • Biological Products